Santa Monica, CA  ·  Sept. 17–19, 2026

Convergence Summit

Advancing ADC & Bi-Specific Medicines

About The Meeting

A focused, working scientific meeting at the forefront of antibody-drug conjugates and bi-specific medicines.

Over three days, participants from leading academic centers, community practices, and life science companies will review emerging clinical and translational data, discuss unmet needs in solid tumors and hematologic malignancies, and explore strategies to design, execute, and implement next-generation antibody-based trials and therapies in routine practice.

Chaired By

Aditya Bardia

UCLA Health

Aditya Bardia

MD, MPH

Professor of Medicine & Director of Translational Research Integration

+

Dr. Aditya Bardia is a distinguished oncologist and physician-scientist at UCLA Health whose research spans breast cancer, antibody-drug conjugates, and precision oncology. He has led landmark clinical trials evaluating novel ADC regimens in solid tumors and is internationally recognized for his work on translational research integration - bridging laboratory discovery and clinical implementation. Dr. Bardia's contributions have shaped guidelines for HER2-targeted therapies and TROP2-directed ADCs, and his leadership in multi-center collaborative networks has accelerated the development of next-generation antibody-based therapies.

Mark Pegram

Stanford Cancer Institute

Mark Pegram

MD

Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology & Associate Director of Clinical Research

+

Dr. Mark Pegram is an internationally recognized oncologist and researcher at the Stanford Cancer Institute, known for his seminal contributions to the development and clinical application of HER2-targeted therapies and bi-specific antibody medicines. As Associate Director of Clinical Research, he oversees a portfolio of investigator-initiated and multi-institutional trials, and has been instrumental in establishing Stanford as a leading site for novel antibody-based trial design. His work continues to define best practices for patient selection, response monitoring, and safety management across both hematologic malignancies and solid tumors.

Faculty

Aditya Bardia

UCLA Health

Aditya Bardia

MD, MPH

Professor of Medicine and Director of Translational Research Integration

Mark Pegram

Stanford Cancer Institute

Mark Pegram

MD

Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology & Associate Director of Clinical Research

Dennis Slamon

UCLA Medical Center

Dennis Slamon

MD, PhD

Professor; Executive Vice Chair for Research; Director, Clinical/Translational Research

Gottfried Konecny

UCLA Health

Gottfried Konecny

MD

Associate Professor & Lead Clinician, Gynecologic Oncology

Jonathan Goldman

UCLA Health

Jonathan Goldman

MD

Professor of Medicine & Associate Director of Early Drug Development, UCLA

Alexandra Drakaki

UCLA Health

Alexandra Drakaki

MD, PhD

Associate Professor of Hematology/Oncology & Urology

Oladapo Yeku

Mass General Hospital

Oladapo Yeku

MD, PhD, FACP, FASCO

Associate Professor & Director of Translational Research, Gynecologic Oncology Program

Sarah Larson

UCLA Health

Sarah Larson

MD

Associate Professor, Department of Medicine, Hematology/Oncology

Alex Adjei

Cleveland Clinic

Alex Adjei

MD, PhD

Chair, Taussig Cancer Institute & Deputy Director, Case Comprehensive Cancer Center

Funda Meric-Bernstam

MD Anderson

Funda Meric-Bernstam

MD

Nellie B. Connally Chair in Breast Cancer & Chair, Investigational Cancer Therapeutics

Vivek Subbiah

Stanford Health Care

Vivek Subbiah

MD

Professor of Medicine and Executive Medical Director, Novel Therapies & Clinical Trial Network

Shiladitya Sengupta

MIT & Harvard Medical School

Shiladitya Sengupta

PhD

Associate Professor

Ravi Salgia

City of Hope

Ravi Salgia

MD, PhD

Professor and Chair, Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology

Tanya Dorff

City of Hope

Tanya Dorff

MD, FASCO

Division Chief, Genitourinary Disease Program & Professor of Medical Oncology

Nataliya Mar

UCI Health

Nataliya Mar

MD

Assistant Professor, Division of Hematology/Oncology, Department of Medicine

Zev Wainberg

UCLA Health

Zev Wainberg

MD, MSc

Professor of Medicine & Co-Director, GI Oncology Program

Isaac Chan

UT Southwestern

Isaac Chan

MD, PhD

Assistant Professor of Internal Medicine

Ana Garrido-Castro

Dana Farber

Ana Garrido-Castro

MD

Director, Triple-Negative Breast Cancer Research & Assistant Professor of Medicine

Agenda

Thursday September 17, 2026

Times and speakers are subject to change.

01

Welcome & Summit Orientation

9:00 AM – 9:15 AM Aditya Bardia & Mark Pegram
02

ADC Target Discovery & Validation: From Biology to Development Readiness

9:15 AM – 10:00 AM Dennis Slamon - UCLA
03

Emerging Targets: The Next Wave of Antibody-Based Oncology

10:30 AM – 11:00 AM Vivek Subbiah - Stanford
04

Payload & Linker Engineering: Stability, Delivery & Therapeutic Index

11:00 AM – 11:30 AM Shiladitya Sengupta - MIT
05

Panel: Designing the Next Wave of Antibody-Based Therapies

11:30 AM – 12:00 PM
06

Building the Next Generation of ADCs

1:30 PM – 2:00 PM Elaine Hurt - AstraZeneca
07

TROP2: Sequencing, Combinations & Development Strategy

2:00 PM – 2:30 PM Shweta Jain - Merck
08

Folate Receptor: Patient Selection & Therapeutic Strategy

2:30 PM – 3:00 PM Gottfried Konecny - UCLA
09

DLL3: Re-Targeting an Established Antigen with New Platforms

3:30 PM – 4:00 PM Jonathan Goldman - UCLA
10

Panel: Target Selection, Differentiation & Development Strategy

4:00 PM – 4:30 PM
Friday September 18, 2026

Times and speakers are subject to change.

01

Adjacent Modalities: Radioligands & Targeted Payload Delivery

8:30 AM – 9:00 AM Tanya Dorff - City of Hope
02

B7-H3: Translational Rationale & Clinical Opportunity

9:00 AM – 9:30 AM Nataliya Mar - UCI
03

Panel: Expanding the Antibody-Based Therapeutic Toolkit

9:30 AM – 10:45 AM
04

Lymphoma: ADC & Multi-Specific Strategies - Practice, Pipeline & Pitfalls

11:00 AM – 11:30 AM Sarah Larson - UCLA
05

Multiple Myeloma: ADCs & Bi-Specific Antibodies in Development and Practice

11:30 AM – 12:00 PM Ajai Chari - UCSF
06

GI Cancers: ADC & Bi-Specific Opportunities Across Emerging Targets

1:30 PM – 2:00 PM Zev Wainberg - UCLA
07

Bladder Cancer: ADC & Bi-Specific Landscape - Targets, Trials & Next Steps

2:00 PM – 2:30 PM Alexandra Drakaki - UCLA
08

Prostate Cancer: ADCs, Bi-Specifics & Targeted Antibody Strategies

2:30 PM – 3:00 PM Terence Friedlander - UCSF
09

Lung Cancer: ADC & Bi-Specific Landscape - Targets, Trials & Integration

3:30 PM – 4:00 PM Ravi Salgia - City of Hope
10

Gynecologic Cancers: ADC & Bi-Specific Opportunities - Patient Selection & Sequencing

4:00 PM – 4:30 PM Oladapo Yeku - MGH
11

Breast Cancer: ADC & Bi-Specific Development Strategy

4:30 PM – 5:00 PM Aditya Bardia - UCLA
12

Panel: Integrating ADCs & Bi-Specifics Across Solid Tumors

5:00 PM – 5:30 PM
Saturday September 19, 2026

Times and speakers are subject to change.

01

Biliary Cancer: ADC & Bi-Specific Landscape - Targets, Trials & Emerging Strategies

8:45 AM – 9:15 AM Rob Iannone - Jazz Pharmaceuticals
02

Preclinical Modeling of ADC Activity and Rationale Combinations

9:15 AM – 9:45 AM Funda Meric-Bernstam - MD Anderson
03

Biomarkers: Patient Selection, Response Monitoring & Resistance Signals

9:45 AM – 10:15 AM Isaac Chan - UT Southwestern
04

Therapeutic Resistance: Mechanisms, Biomarkers & Next-Generation Strategies

11:00 AM – 11:30 AM Ana Garrido-Castro - Dana Farber
05

Panel: Biomarkers, Resistance & the Next Development Frontier

11:30 AM – 12:00 PM
06

Summit Synthesis & Next Steps

12:00 PM – 12:15 PM Aditya Bardia & Mark Pegram

Sponsors